New Developments in Radiation Therapy for Head and Neck Cancer: Intensity-Modulated Radiation Therapy and Hypoxia Targeting

Seminars in Oncology

Volumn 35, Issue 3, 2008, Pages 236-250

  Lee, Nancy Y ^a   Le, Quynh Thu ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOGEN; CARBOPLATIN; CISPLATIN; CYTOTOXIN; DINITROBENZAMIDE MUSTARD; ERYTHROPOIETIN; FLUOROURACIL; NICOTINAMIDE; NIMORAZOLE; NITROIMIDAZOLE DERIVATIVE; PR 104; TIRAPAZAMINE; TUMOR MARKER;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CARCINOMA; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; IONIZING RADIATION; LARYNX CARCINOMA; NASOPHARYNX CARCINOMA; OROPHARYNX CARCINOMA; PARANASAL SINUS CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; THYROID CARCINOMA; TREATMENT PLANNING; TUMOR BLOOD FLOW;

ADVANCE CARE PLANNING; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; FORECASTING; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 44649092578     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.03.003     Document Type: Article

References (134)

1. Chui C.S., and Spirou S.V. Inverse planning algorithms for external beam radiation therapy. Med Dosimetry 26 (2001) 189-197
2. Chui C.S., Chan M.F., Yorke E., et al. Delivery of intensity-modulated radiation therapy with a conventional multileaf collimator: comparison of dynamic and segmental methods. Med Physics 28 (2001) 2441-2449
3. Xia P., Fu K.K., Wong G.W., et al. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 48 (2000) 329-337
4. Huang D., Xia P., Akazawa P., et al. Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys 56 (2003) 158-168
5. Gregoire V. Implementation of intensity-modulated radiation therapy in head and neck tumors: what are the important data for biological optimization?. Rays 29 (2004) 271-274
6. de Neve W., Duthoy W., Claus F., et al. Dose conformation in IMRT for head and neck tumors: which solution to apply?. Cancer Radiother 6 Suppl 1 (2002) 32s-36s
7. Eisbruch A., Kim H.M., Terrell J.E., et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 30 (2001) 695-704
8. Chao K.S., Deasy J.O., Markman J., et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 49 (2001) 907-916
9. Lee N.Y., O'Meara W., Chan K., et al. Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys (2007) 459-468
10. Lee N., Xia P., Quivey J.M., et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53 (2002) 12-22
11. Chao K.S., Ozyigit G., Tran B.N., et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 55 (2002) 312-321
12. Lee N., Xia P., Fischbein N.J., et al. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 57 (2003) 49-60
13. Dawson L.A., Anzai Y., Marsh L., et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 46 (2000) 1117-1126
14. Gregoire V., Levendag P., Ang K.K., et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol 69 (2003) 227-236
15. Gregoire V., Eisbruch A., Hamoir M., et al. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol 79 (2006) 15-20
16. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Physics 51 (2001) 880-914
17. Xia P., Pickett B., Vigneault E., et al. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 51 (2001) 244-254
18. Lee N, Akazawa C, Akazawa P, et al. A forward-planned treatment technique using multisegments in the treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 59:584-94.
19. Xia P., Lee N., Liu Y.M., et al. A study of planning dose constraints for treatment of nasopharyngeal carcinoma using a commercial inverse treatment planning system. Int J Radiat Oncol Biol Phys 59 (2004) 886-896
20. Boyer A.L., and Yu C.X. Intensity-modulated radiation therapy with dynamic multileaf collimators. Semin Radiat Oncol 9 (1999) 48-59
21. Michalski J., Purdy J.A., Gaspar L., et al., Radiation Therapy Oncology Group. Research Plan. 2002-2006. Image-Guided Radiation Therapy Committee. Int J Radiat Oncol Biol Phys 51 (2001) 60-65
22. Xia P., and Verhey L.J. Delivery systems of intensity-modulated radiotherapy using conventional multileaf collimators. Med Dosimetry 26 (2001) 169-177
23. Lee N., Puri D.R., Blanco A.I., et al. Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck 29 (2007) 387-400
24. Eisbruch A. Intensity-modulated radiotherapy of head-and-neck cancer: encouraging early results. Int J Radiat Oncol Biol Phys 53 (2002) 1-3
25. Daly M.E., Lieskovsky Y., Pawlicki T., et al. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head Neck 29 (2007) 211-220
26. Eisbruch A., Schwartz M., Rasch C., et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT?. Int J Radiat Oncol Biol Phys 60 (2004) 1425-1439
27. Lee N.Y., de Arruda F.F., Puri D.R., et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66 (2006) 966-974
28. Yao M., Dornfeld K.J., Buatti J.M., et al. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma-the University of Iowa experience. Int J Radiat Oncol Biol Phys 63 (2005) 410-421
29. Kam M.K., Chau R.M., Suen J., et al. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys 56 (2003) 145-157
30. Hunt M.A., Zelefsky M.J., Wolden S., et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 49 (2001) 623-632
31. Kwong D.L., Pow E.H., Sham J.S., et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer 101 (2004) 1584-1593
32. Kam M.K., Teo P.M., Chau R.M., et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 60 (2004) 1440-1450
33. Wolden S.L., Chen W.C., Pfister D.G., et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 64 (2006) 57-62
34. Kam M.K.M., Leung S.-F., Zee B., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25 (2007) 4873-4879
35. Bucci M., Xia P., Lee N., et al. Intensity modulated radiation therapy for carcinoma of the nasopharynx: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 60 (2004) 317-318
36. Kyzas P.A., Cunha I.W., and Ioannidis J.P. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 11 (2005) 1434-1440
37. Qian C.N., Zhang C.Q., Guo X., et al. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 88 (2000) 255-261
38. Krishna S.M., James S., and Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 115 (2006) 85-90
39. Lin A., Kim H.M., Terrell J.E., et al. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 57 (2003) 61-70
40. Eisbruch A., Marsh L.H., Dawson L.A., et al. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 59 (2004) 28-42
41. Chao K.S., Ozyigit G., Blanco A.I., et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 59 (2004) 43-50
42. de Arruda F.F., Puri D.R., Zhung J., et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 64 (2006) 363-373
43. Studer G., Lutolf U.M., Davis J.B., et al. IMRT in hypopharyngeal tumors. Strahlenther Onkol 182 (2006) 331-335
44. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
45. Combs S.E., Konkel S., Schulz-Ertner D., et al. Intensity modulated radiotherapy (IMRT) in patients with carcinomas of the paranasal sinuses: clinical benefit for complex shaped target volumes. Radiat Oncol 1 (2006) 23
46. Claus F., Mijnheer B., Rasch C., et al. Report of a study on IMRT planning strategies for ethmoid sinus cancer. Strahlenther Onkol 178 (2002) 572-576
47. Hoppe B.S., Stegman L.D., Zelefsky M.J., et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting-the MSKCC experience. Int J Radiat Oncol Biol Phys 67 (2007) 691-702
48. Daly M.E., Chen A.M., Bucci M.K., et al. Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys 67 (2007) 151-157
49. Claus F., Boterberg T., Ost P., et al. Short term toxicity profile for 32 sinonasal cancer patients treated with IMRT. Can we avoid dry eye syndrome?. Radiother Oncol 64 (2002) 205-208
50. Chen A.M., Daly M.E., Bucci M.K., et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?. Int J Radiat Oncol Biol Phys 67 (2007) 151-157
51. Nutting C.M., Convery D.J., Cosgrove V.P., et al. Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiother Oncol 60 (2001) 173-180
52. Posner M.D., Quivey J.M., Akazawa P.F., et al. Dose optimization for the treatment of anaplastic thyroid carcinoma: a comparison of treatment planning techniques. Int J Radiat Oncol Biol Phys 48 (2000) 475-483
53. Rosenbluth B.D., Serrano V., Hunt M.A., et al. Intensity-modulated radiation therapy for the treatment of non-anaplastic thyroid cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1419-1426
54. Chen Y.J., Kuo J.V., Ramsinghani N.S., et al. Intensity-modulated radiotherapy for previously irradiated, recurrent head-and-neck cancer. Med Dosimetry 27 (2002) 171-176
55. Lu T.X., Mai W.Y., Teh B.S., et al. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 58 (2004) 682-687
56. Lee N., Chan K., Bekelman J.E., et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 68 (2007) 731-740
57. Tatum J.L., Kelloff G.J., Gillies R.J., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82 (2006) 699-757
58. Gatenby R.A., Kessler H.B., Rosenblum J.S., et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14 (1988) 831-838
59. Wendling P., Manz R., Thews G., et al. Heterogeneous oxygenation of rectal carcinomas in humans: a critical parameter for preoperative irradiation?. Adv Exp Med Biol 180 (1984) 293-300
60. Brizel D.M., Dodge R.K., Clough R.W., et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53 (1999) 113-117
61. Nordsmark M., and Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57 (2000) 39-43
62. Rudat V., Stadler P., Becker A., et al. Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlenther Onkol 177 (2001) 462-468
63. Brizel D.M., Prosnitz R.G., Hunter S., et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1418-1423
64. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
65. Stone H.B., Brown J.M., Phillips T.L., et al. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Radiat Res 136 (1993) 422-434
66. Raleigh J.A., Calkins-Adams D.P., Rinker L.H., et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 58 (1998) 3765-3768
67. Evans S.M., Hahn S., Pook D.R., et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 60 (2000) 2018-2024
68. Varghese A.J., Gulyas S., and Mohindra J.K. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res 36 (1976) 3761-3765
69. Ljungkvist A.S., Bussink J., Kaanders J.H., et al. Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167 (2007) 127-145
70. Evans S.M., and Koch C.J. Prognostic significance of tumor oxygenation in humans. Cancer Lett 195 (2003) 1-16
71. Raleigh J.A., Chou S.C., Arteel G.E., et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 151 (1999) 580-589
72. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62 (2002) 7066-7074
73. Stroka D.M., Burkhardt T., Desbaillets I., et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15 (2001) 2445-2453
74. Zundel W., Schindler C., Haas-Kogan D., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14 (2000) 391-396
75. Zelzer E., Levy Y., Kahana C., et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 17 (1998) 5085-5094
76. Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
77. Janssen H.L., Haustermans K.M., Sprong D., et al. HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 54 (2002) 1537-1549
78. Chi J.T., Wang Z., Nuyten D.S., et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3 (2006) e47
79. Winter S.C., Buffa F.M., Silva P., et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 67 (2007) 3441-3449
80. Le Q.T., Kong C., Lavori P.W., et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69 (2007) 167-175
81. Riedel F., Gotte K., Schwalb J., et al. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 257 (2000) 332-336
82. Salven P., Manpaa H., Orpana A., et al. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 3 (1997) 647-651
83. Imagawa S., Yamaguchi Y., Higuchi M., et al. Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea-hypopnea syndrome. Blood 98 (2001) 1255-1257
84. Dunst J., Stadler P., Becker A., et al. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 177 (2001) 469-473
85. Le Q.T., Sutphin P.D., Raychaudhuri S., et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9 (2003) 59-67
86. Nordsmark M., Eriksen J.G., Gebski V., et al. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol (2007)
87. Petrik D., Lavori P.W., Cao H., et al. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 24 (2006) 5291-5297
88. Overgaard J., Eriksen J.G., Nordsmark M., et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
89. Overgaard J., and Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6 (1996) 10-21
90. Watson E.R., Halnan K.E., Dische S., et al. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. Br J Radiol 51 (1978) 879-887
91. Dische S., Anderson P.J., Sealy R., et al. Carcinoma of the cervix-anaemia, radiotherapy and hyperbaric oxygen. Br J Radiol 56 (1983) 251-255
92. Sheldon P.W., Foster J.L., and Fowler J.F. Radiosensitization of C3H mouse mammary tumours by a 2-nitroimidazole drug. Br J Cancer 30 (1974) 560-565
93. Brown J.M. Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro 7-0582. Radiat Res 64 (1975) 633-647
94. Lee D.J., Pajak T.F., Stetz J., et al. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). Int J Radiat Oncol Biol Phys 16 (1989) 465-470
95. Lee D.J., Cosmatos D., Marcial V.A., et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 32 (1995) 567-576
96. Overgaard J., Hansen H.S., Anderson A.P., et al. Misonidazole combined with split course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA study. Int J Radiat Oncol Biol Phys 16 (1989) 1065-1068
97. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 46 (1998) 135-146
98. Wasserman T.H., Lee D.J., Cosmatos D., et al. Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG). Radiother Oncol 20 Suppl 1 (1991) 129-135
99. Dische S., Saunders M.I., Lee M.E., et al. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer 35 (1977) 567-579
100. Coleman C.N., Wasserman T.H., Urtasun R.C., et al. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule. Int J Radiat Oncol Biol Phys 12 (1986) 1105-1108
101. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
102. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
103. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
104. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
105. Taghian A.G., Abi-Raad R., Assaad S.I., et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 23 (2005) 1951-1961
106. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
107. Kaanders J.H., Pop L.A., Marres H.A., et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 769-778
108. Haffty B.G., Son Y.H., Papac R., et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. J Clin Oncol 15 (1997) 268-276
109. Dobrowsky W., Naude J., Widder J., et al. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys 42 (1998) 803-806
110. Dobrowsky W., and Naude J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 57 (2000) 119-124
111. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23 (2005) 79-87
112. Le Q.T., Taira A., Budenz S., et al. Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. Cancer 106 (2006) 1940-1949
113. Wilson W.R., Hicks K.O., Pullen S.M., et al. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 167 (2007) 625-636
114. Patterson A.V., Ferry D.M., Edmunds S.J., et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res 13 (2007) 3922-3932
115. Giaccia A., Siim B.G., and Johnson R.S. HIF-1 as a target for drug development. Nat Rev Drug Discov 2 (2003) 803-811
116. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26 (2007) 341-352
117. Rapisarda A., Uranchimeg B., Scudiero D.A., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62 (2002) 4316-4324
118. Mabjeesh N.J., Escuin D., LaVallee T.M., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
119. Mabjeesh N.J., Post D.E., Willard M.T., et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62 (2002) 2478-2482
120. Kong X., Lin Z., Liang D., et al. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26 (2006) 2019-2028
121. Yeo E.J., Chun Y.S., Cho Y.S., et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95 (2003) 516-525
122. Welsh S., Williams R., Kirkpatrick L., et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3 (2004) 233-244
123. Welsh S., Williams R., Birmingham A., et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther 2 (2003) 235-243
124. Melillo G., Sausville E.A., Cloud K., et al. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 59 (1999) 5433-5437
125. Cairns R.A., Papandreou I., Sutphin P.D., et al. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci U S A 104 (2007) 9445-9450
126. Moeller B.J., Cao Y., Li C.Y., et al. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
127. Aebersold D.M., Burri P., Beer K.T., et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61 (2001) 2911-2916
128. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53 (2002) 1192-1202
129. Beasley N.J., Leek R., Alam M., et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62 (2002) 2493-2497
130. Hui E.P., Chan A.T., Pezzella F., et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8 (2002) 2595-2604
131. Beasley N.J., Wykoff C.C., Watson P.H., et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61 (2001) 5262-5267
132. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7 (2001) 3399-3403
133. Winter S.C., Shah K.A., Han C., et al. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107 (2006) 757-766
134. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735